Provided by The University of Texas MD Anderson Cancer Center
This activity is supported by an educational grant from Pharmacyclics LLC.
This activity is jointly-provided by ASiM CE, LLC.
The advent of targeted therapies has shifted paradigms for the management of patients with chronic lymphocytic leukemia (CLL), providing novel first- and subsequent-line treatment options for many patients. The effective use of these evolving strategies for this type of malignancy hinges primarily on clinicians’ proficiency regarding the latest clinical trial and real-world data on the safety, efficacy, and appropriate use of these novel agents in patient management. This interactive activity features 2 leading experts in CLL who discuss and debate the latest advances regarding novel and emerging targeted therapies for patients with CLL, as well as discuss the evolving role of prognostic molecular biomarkers in targeted therapy initiation and treatment selection, highlighting key data presented at the 2018 Annual Meeting and Exposition of the American Society of Hematology (ASH). Case-based scenarios will also provide clinicians with the opportunity to explore management strategies, incorporating the most recent clinical data, into real-world simulations of treatment decision-making.
H/O HCPs will be better able to interpret the most recent data, approvals, & guidelines regarding the use of targeted therapies as part of CLL treatment paradigms.
H/O HCPs will be more cognizant of unique AEs of targeted therapy options that influence treatment selection & management & better able to implement treatment-specific AE management strategies. (Knowledge, Competence)
H/O HCPs will be better able to implement & utilize cytogenic testing to diagnose CLL, determine prognosis, and inform treatment selection, particularly regarding the use of targeted therapies. (Knowledge, Competence)
H/O HCPs will be better able to utilize the most recent efficacy/safety data to inform appropriate CLL targeted therapy selection & management, including response assessment, modification, and AE management. (Knowledge, Competence, Performance)
This activity is intended for hematology and oncology clinicians (physicians, physician assistants, nurse practitioners) as well as other healthcare providers involved in the management of patients with CLL.
At the conclusion of this educational activity, the participant should be able to:
Evaluate the most recent data on the efficacy & clinical utility of targeted therapies for newly diagnosed & R/R CLL (Knowledge, Competence)
Compare the AE and tolerability profiles, as well as relevant management strategies, of approved & investigational CLL targeted therapies (Knowledge, Competence)
Analyze evolving evidence regarding molecular biomarkers & risk stratification as part of targeted therapy initiation & selection (Knowledge, Competence)
Incorporate clinical trial & real world data into targeted therapy treatment selection & management, particularly regarding AEs, as part of individualized CLL treatment plans (Knowledge, Competence, Performance)
Conflict Of Interest Disclosure Policy
The Accreditation Council for Continuing Medical Education has announced standards and guidelines to ensure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.
The University of Texas MD Anderson Cancer Center has, through a formal review process, made every attempt to resolve all potential conflicts of interest prior to this activity. For information on this process, please contact the CME/Conference Management at 713-792-5357.
The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
Nitin Jain, MD (Course Director) Associate Professor of Medicine Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas
Dr. Jain has disclosed the following relevant financial relationships: Grant or research support: Pharmacyclics, AbbVie, Genentech, Bristol-Myers Squibb, Astra-Zeneca, Verastem, Adaptive Biotechnologies Paid consultant: Pharmacyclics, AbbVie, Janssen, Astra-Zeneca, Verastem, Adaptive Biotechnologies Honoraria: Pharmacyclics, AbbVie, Janssen, Astra-Zeneca, Verastem, Adaptive Biotechnologies
Jennifer R. Brown, MD, PhD Associate Professor of Medicine Harvard Medical School Director, CLL Center Dana-Farber Cancer Institute Boston, Massachusetts
Dr. Brown has disclosed the following relevant financial relationships: Grant or research support: Gilead, Loxo, Sun, Verastem Paid consultant: AbbVie, Acerta, Juno/Celgene, Kite, Sunesis, TG Therapeutics, Verastem Honoraria: Janssen, Teva Membership advisory and committees: Biogene, Morphosys, Invectys
PLANNING COMMITTEE MEMBERS/COMMERCIAL INTERESTS
The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
Tamara Greiner, MA, CHCP Daniel Guinee Alexandra Marsillo, PhD
Nitin Jain, MD, has disclosed the following relevant financial relationships: Grant or research support: Pharmacyclics, AbbVie, Genentech, Bristol-Myers Squibb, Astra-Zeneca, Verastem, Adaptive Biotechnologies Paid consultant: Pharmacyclics, AbbVie, Genentech, Bristol-Myers Squibb, Astra-Zeneca, Verastem, Adaptive Biotechnologies Honoraria: Pharmacyclics, AbbVie, Astra-Zeneca, Verastem, Adaptive Biotechnologies
CME ACTIVITY REVIEWERS/APPROVERS
Diane C. Bodurka, MD, BS, MPH Dhakshina Ganeshan, MD Peter Norman, MD
ASiM CE, LLC, planners and reviewers have disclosed no financial relationships with pharmaceutical or medical product manufacturers.
AMA PRA Category 1 Credit(s)TM
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this internet enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME CERTIFICATES AND ATTENDANCE CERTIFICATES
Certificates awarding AMA PRA Category 1 CreditTM or certificates documenting participation will be issued immediately to participants when an individual completes the post-test and evaluation.
Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. You must participate in the entire activity to receive credit. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.